PMID: identifiant
de la référence Pubmed : |
 |
 (22409820) |
|
| titre : |
|
New biomarkers in T-cell lymphomas. |
|
| auteur(s) : |
|
Bettina Bisig1, 2, Philippe Gaulard3, 4, Laurence De Leval ( ) 1, 2, 5 |
|
| laboratoire : |
|
|
|
| résumé : |
|
Peripheral T-cell lymphomas (PTCLs) are heterogeneous and uncommon malignancies characterized by an aggressive clinical course and a mostly poor outcome with current treatment strategies. The recent genome-wide molecular characterization of several entities has provided novel insights into their pathobiology and led to the identification of new biomarkers with diagnostic, prognostic or therapeutic implications for PTCL patients. Cell lineage and differentiation antigens (markers of γδ or NK lineage, of cytotoxicity, of follicular helper T cells) reflect the tumour's biological behaviour, and their detection in tissue samples may refine the diagnostic and prognostic stratification of the patients. Previously unrecognized gene rearrangements are being discovered (ITK-SYK translocation, IRF4/MUM1 and DUSP22 rearrangements), and may serve as diagnostic genetic markers. Deregulated molecules within oncogenic pathways (NF-κB, Syk, PDGFRα) and immunoreactive cell-surface antigens (CD30, CD52) have been brought to the fore as potential targets for guiding the development of novel therapies. |
|
| domaine : |
|
Sciences du Vivant/Biochimie, Biologie Moléculaire
|
|
langue du texte
intégral : |
|
Anglais |
|
| ISSN : |
|
1532-1924 |
|
|
| type de publication : |
|
Articles dans des revues avec comité de lecture |
|
| DOI : |
|
10.1016/j.beha.2012.01.004 |
|
| journal : |
|
| Best Practice and Research: Clinical Haematology (Best Pract Res Clin Haematol) |
| Publisher |
Elsevier |
| ISSN |
1521-6926 |
|
|
| Audience : |
|
internationale |
|
| date de publication : |
|
03/2012 |
|
date de publication
électronique : |
|
07/02/2012 |
|
| volume : |
|
25 |
|
| numéro : |
|
1 |
|
| page, identifiant, ... : |
|
13-28 |
|
|
| mots-clés auteur : |
|
peripheral T-cell lymphomas – biomarkers – translocations – gene expression profiling – targeted therapy – prognosis |
|
| contrat, financement : |
|
This work was supported by the Belgian National Fund for Scientific Research (Fonds de la Recherche Scientifique, FNRS), the Belgian Cancer Plan, and the French Foundation for Medical Research (Fondation pour la Recherche Médicale, FRM). Bettina Bisig and Laurence de Leval are a Scientific Research Worker-Télévie and a Senior Research Associate of the FNRS, respectively. |
|
